Max Wolff

Dr Max Wolff is a psychedelic researcher from Germany. Dr Wolff is Head of Psychotherapy Training & Research at the MIND Foundation in Berlin. He is academic affiliation is with Charité Berlin University Hospital (for the EPIsoDE trial).

His academic journey began at Technische Universität Dresden in 2013 as a Research Assistant, and he received his Diploma in Psychology from Justus-Liebig-Universität Giessen in 2012. He also attended the European Graduate School in Addiction Research from 2013 to 2015. He was a faculty member at the Departments of Psychology and Psychiatry and Psychotherapy at Technische Universität Dresden (University of Dresden; until 2021), where he obtained his Doctorate in 2017.

Dr Wolff’s research is primarily focused on the psychotherapeutic mechanisms and contextual conditions of psychedelic-occasioned psychological change. He aims to make the findings of psychotherapy research applicable to the practice of psychedelic therapy. His postdoctoral research has delved into behavioural change, cognitive control, and self-control failures among individuals with addiction. One of his significant contributions is a study published in Frontiers in Psychiatry in 2020, which examines the influence of psychedelic therapy on experiential avoidance and acceptance through a cognitive-behavioural (CBT) framework.

As the Head of Psychotherapy Training and Research at the MIND Foundation, Dr Wolff directs the Foundation’s APT Program, an international training in psychedelic-augmented psychotherapy for psychotherapists, psychiatrists, and other mental health professionals. He is also involved as a researcher and study therapist in the EPIsoDE trial, a Phase IIb clinical trial investigating the safety and efficacy of psilocybin for treatment-resistant depression at the Central Institute of Mental Health (CIMH) Mannheim, Germany, and Charité University Medicine Berlin.

Dr Wolff has presented his work at various conferences, including the Interdisciplinary Conference on Psychedelic Research in 2020 and Insight 2021. His work is instrumental in furthering our understanding of the therapeutic potential of psychedelics.